The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples
Open accessAbstract
SynergyFinder (https://synergyfinder.fimm.fi) is a free web-application for interactive analysis and visualization of multi-drug combination response data. Since its first release in 2017, SynergyFinder has become a popular tool for multi-dose combination data analytics, partly because the development of its functionality and graphical interface has been driven by a diverse user community, including both chemical biologists and computational scientists. Here, we describe the latest upgrade of this community-effort, SynergyFinder release 3.0, introducing a number of novel features that support interactive multi-sample analysis of combination synergy, a novel consensus synergy score that combines multiple synergy scoring models, and an improved outlier detection functionality that eliminates false positive results, along with many other post-analysis options such as weighting of synergy by drug concentrations and distinguishing between different modes of synergy (potency and efficacy). Based on user requests, several additional improvements were also implemented, including new data visualizations and export options for multi-drug combinations. With these improvements, SynergyFinder 3.0 supports robust identification of consistent combinatorial synergies for multi-drug combinatorial discovery and clinical translation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE TOXICITY OF POISONS APPLIED JOINTLY1
BLISS, C. I. (1939) · Annals of Applied Biology · doi:10.1111/j.1744-7348.1939.tb06990.x · Cited by 2,419
(1953) · PubMed · Cited by 942
SynergyFinder 2.0: visual analytics of multi-drug combination synergies
Ianevski, A., Giri, A. K., & Aittokallio, T. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa216 · Cited by 873
Self-citationSearching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model
Yadav, B., Wennerberg, K., Aittokallio, T., & Tang, J. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.09.001 · Cited by 845 · cited 2×
“The ZIP synergy model was not included in the consensus scoring as it shares the same multiplicative survival principle as Bliss model, thereby potentially biasing the consensus synergy interpretation (see Supplementary Figure S1).”
Self-citationCombenefit: an interactive platform for the analysis and visualization of drug combinations
Di Veroli, G. Y., Fornari, C., Wang, D., Mollard, S., Bramhall, J. L., Richards, F. M., & Jodrell, D. I. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw230 · Cited by 736
SynergyFinder: a web application for analyzing drug combination dose–response matrix data
Ianevski, A., He, L., Aittokallio, T., & Tang, J. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx162 · Cited by 530
Self-citationHolbeck, S. L., Camalier, R., Crowell, J. A., Govindharajulu, J. P., Hollingshead, M., Anderson, L. W., Polley, E., Rubinstein, L., Srivastava, A., Wilsker, D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0489 · Cited by 359
Independent Drug Action in Combination Therapy: Implications for Precision Oncology
Plana, D., Palmer, A. C., & Sorger, P. K. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0212 · Cited by 307
Naci, H., Davis, C., Savović, J., Higgins, J. P. T., Sterne, J. A. C., Gyawali, B., Romo-Sandoval, X., Handley, N., & Booth, C. M. (2019) · BMJ · doi:10.1136/bmj.l5221 · Cited by 243
Rational Cancer Treatment Combinations: An Urgent Clinical Need
Boshuizen, J., & Peeper, D. S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.031 · Cited by 210
Quantifying drug combination synergy along potency and efficacy axes
Meyer, C. T., Wooten, D. J., Paudel, B. B., Bauer, J., Hardeman, K. N., Westover, D., Lovly, C. M., Harris, L. A., Tyson, D. R., & Quaranta, V. (2019) · Cell Systems · doi:10.1016/j.cels.2019.01.003 · Cited by 202
Prediction of drug combination effects with a minimal set of experiments
Ianevski, A., Giri, A. K., Gautam, P., Kononov, A., Potdar, S., Saarela, J., Wennerberg, K., & Aittokallio, T. (2019) · Nature Machine Intelligence · doi:10.1038/s42256-019-0122-4 · Cited by 175
Self-citationLong-acting antiretrovirals: a new era for the management and prevention of HIV infection
Thoueille, P., Choong, E., Cavassini, M. L., Buclin, T., & Decosterd, L. A. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab324 · Cited by 148
Two-Drug Combinations as First-Step Antihypertensive Treatment
Mancia, G., Rea, F., Corrao, G., & Grassi, G. M. (2019) · Circulation Research · doi:10.1161/circresaha.118.313294 · Cited by 144
Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls
Vlot, A. H. C., Aniceto, N., Menden, M. P., Ulrich-Merzenich, G. S., & Bender, A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.09.002 · Cited by 128
Recent advances in combinatorial drug screening and synergy scoring
Pemovska, T., Bigenzahn, J. W., & Superti‐Furga, G. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.07.008 · Cited by 125
Kurtz, S. E., Eide, C. A., Kaempf, A. J., Khanna, V., Savage, S. L., Rofelty, A., English, I. A., Ho, H., Pandya, R., Bolosky, W. J., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1703094114 · Cited by 115
Wooten, D. J., Meyer, C. T., Lubbock, A. L. R., Quaranta, V., & Lopez, C. F. (2021) · Nature Communications · doi:10.1038/s41467-021-24789-z · Cited by 97
SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy
Ianevski, A., Kononov, A., Timonen, S., Aittokallio, T. A., & Giri, A. K. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007604 · Cited by 72
Self-citationDrug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses
White, J. M., Schiffer, J. T., Bender Ignacio, R. A., Xu, S., Kainov, D., Ianevski, A., Aittokallio, T., Frieman, M., Olinger, G. G., & Polyak, S. J. (2021) · mBio · doi:10.1128/mbio.03347-21 · Cited by 64
Self-citationUncovering Scaling Laws to Infer Multidrug Response of Resistant Microbes and Cancer Cells
Wood, K. B., Wood, K. C., Nishida, S., & Cluzel, P. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.007 · Cited by 56
synergy: a Python library for calculating, analyzing and visualizing drug combination synergy
Wooten, D. J., & Albert, R. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa826 · Cited by 50
Davies, G., Boeree, M. J., Hermann, D., & Höelscher, M. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002851 · Cited by 43
Patient-tailored design for selective co-inhibition of leukemic cell subpopulations
Ianevski, A., Lahtela, J., Javarappa, K. K., Sergeev, P., Ghimire, B. R., Gautam, P., Vähä-Koskela, M. J. V., Turunen, L., Linnavirta, N., Kuusanmäki, H. A., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe4038 · Cited by 43
Self-citationNguyen, L. C., Naulaerts, S., Bomane, A., Bruna, A., Ghislat, G., & Ballester, P. J. (2021) · Biomedicines · doi:10.3390/biomedicines9101319 · Cited by 41
Amzallag, A., Ramaswamy, S., & Benes, C. H. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2642-7 · Cited by 37
Wang, D. Y. Q., Hensman, J. J., Kutkaite, G., Toh, T. S., Galhoz, A., GDSC Screening Team, Lightfoot, H. W., Yang, W., Soleimani, M., Barthorpe, S., et al. (2020) · eLife · doi:10.7554/elife.60352 · Cited by 30
Genome-wide off-targets of drugs: risks and opportunities
Giri, A. K., Ianevski, A., & Aittokallio, T. A. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09491-7 · Cited by 18
Self-citationCImbinator: a web-based tool for drug synergy analysis in small- and large-scale datasets
Flobak, Å., Vázquez, M., Lægreid, A., & Valencia, A. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx161 · Cited by 16
Giri, A. K., & Ianevski, A. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.1991306 · Cited by 16
Self-citationPreclinical cancer research suffers another reproducibility blow
Mullard, A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/d41573-022-00012-6 · Cited by 7
Research works printed but not linked: 2
- Meyer, 2022, Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials, Pharm. Stat., 21, 671, 10.1002/pst.2194 · doi:10.1002/pst.2194
- Berenbaum, 1989, What is synergy?, Pharmacol. Rev., 41, 93
Cited by
Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones
Liang, D., Feng, Y., Zandkarimi, F., Wang, H., Zhang, Z., Kim, J., Cai, Y., Gu, W., Stockwell, B. R., & Jiang, X. (2023) · Cell · doi:10.1016/j.cell.2023.05.003 · Cited by 722
The present and future of the Cancer Dependency Map
Arafeh, R., Shibue, T., Dempster, J. M., Hahn, W. C., & Vazquez, F. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-024-00763-x · Cited by 454
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0177 · Cited by 308
Mantione, M. E., Meloni, M., Sana, I., Bordini, J., Del Nero, M., Riba, M., Ranghetti, P., Perotta, E., Ghia, P., Scarfò, L., et al. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-06602-z · Cited by 57
“Genes were considered “ differentially expressed ” if they satis fi ed both the following conditions: nominal p value 0.01 and absolute value of log 2 FC ≥ 1.”
BackgroundInfluentialStatistical Assessment of Drug Synergy from In Vivo Combination Studies Using Mouse Tumor Models
Mao, B., & Guo, S. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0243 · Cited by 27
Metadata
- Authors
- Ianevski, A., Giri, A. K., & Aittokallio, T.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-05-17
- Volume
- 50
- Issue
- W1
- Pages
- W739-W743
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W4225910596
- Cited by
- 778
- References
- 31
- FWCI
- 69.94
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Academy of Finland (326238, 340141, 345803, 344698)
- European Union's Horizon 2020 (ERA PerMed JAKSTAT-TARGET)
- Cancer Society of Finland
- Sigrid Jusélius Foundation
- Maud Kuistila Memorial Foundation
- K. Albin Johanssons stiftelse sr Foundation
- Norwegian Cancer Society (216104)
- Fuugin foundation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.